Silverback Therapeutics

Silverback Therapeutics

Biotechnology, El Camino Real, Seattle, , 92130, Washington, 11682, United States, 51-200 Employees

silverbacktx.com

  • twitter
  • LinkedIn

Who is SILVERBACK THERAPEUTICS

We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatmen...

Read More

map
  • 11682 El Camino Real, Seattle, Washington, 92130, United States Headquarters: 11682 El Camino Real, Seattle, Washington, 92130, United States
  • 2016 Date Founded: 2016
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SILVERBACK THERAPEUTICS

Silverback Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Silverback Therapeutics

Answer: Silverback Therapeutics's headquarters are located at El Camino Real, Seattle, , 92130, Washington, 11682, United States

Answer: Silverback Therapeutics's official website is https://silverbacktx.com

Answer: Silverback Therapeutics's revenue is $25 Million to $50 Million

Answer: Silverback Therapeutics's SIC: 2834

Answer: Silverback Therapeutics's NAICS: 561110

Answer: Silverback Therapeutics has 51-200 employees

Answer: Silverback Therapeutics is in Biotechnology

Answer: Silverback Therapeutics contact info: Phone number: Website: https://silverbacktx.com

Answer: We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access